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Abstract
Background: Colorectal cancer (CRC) is with approximately 1 million cases the third most common cancer worldwide.
Extensive research is ongoing to decipher the underlying genetic patterns with the hope to improve early cancer diagnosis
and treatment. In this direction, the recent progress in next generation sequencing technologies has revolutionized the field
of cancer genomics. However, one caveat of these studies remains the large amount of genetic variations identified and
their interpretation.
Methodology/Principal Findings: Here we present the first work on whole exome NGS of primary colon cancers. We
performed 454 whole exome pyrosequencing of tumor as well as adjacent not affected normal colonic tissue from
microsatellite stable (MSS) and microsatellite instable (MSI) colon cancer patients and identified more than 50,000 small
nucleotide variations for each tissue. According to predictions based on MSS and MSI pathomechanisms we identified eight
times more somatic non-synonymous variations in MSI cancers than in MSS and we were able to reproduce the result in four
additional CRCs. Our bioinformatics filtering approach narrowed down the rate of most significant mutations to 359 for MSI
and 45 for MSS CRCs with predicted altered protein functions. In both CRCs, MSI and MSS, we found somatic mutations in
the intracellular kinase domain of bone morphogenetic protein receptor 1A, BMPR1A, a gene where so far germline
mutations are associated with juvenile polyposis syndrome, and show that the mutations functionally impair the protein
function.
Conclusions/Significance: We conclude that with deep sequencing of tumor exomes one may be able to predict the
microsatellite status of CRC and in addition identify potentially clinically relevant mutations.
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Introduction
Colorectal cancer is the third most common cancer with about
1 million cases worldwide. Over the last decades it has become
clear that CRC evolves through multiple pathways and that these
pathways can be roughly defined on the basis of molecular
patterns such as the integrity of the mismatch repair system
(MMR) or mutational and epigenetic patterns. Deficiency in the
MMR is reflected in DNA microsatellite instability (MSI) which
has also been associated with treatment outcome, but which
needs to be further validated in additional clinical studies
[1,2,3,4,5,6].
High-throughput Sanger sequencing studies on the other hand
have shown that the mutation frequency of candidate cancer genes
might be much higher than expected, and that the particular
combination of mutations might influence the tumor’s properties
[7,8,9,10,11]. With the development of next-generation sequenc-
ing (NGS) technologies the sequencing throughput has dramati-
cally increased and the costs have decreased. In addition, and
especially important for clinical settings, NGS can be applied to
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as highly degraded DNA which is routinely prepared in pathology
departments or found in ancient DNA [12,13]. Several studies
have used NGS technologies for the identification of the
underlying mutation in monogenetic diseases [14,15]. However,
only a limited number of studies report on next-generation
sequencing to identify new candidate cancer genes; one of the
earliest studies examined cytogenetically normal acute myeloid
leukemia, and breast cancer genomes [16,17]. In addition, studies
on malignant melanoma and small-cell lung cancer cell lines have
provided first insights into genomic alterations induced by
ultraviolet light exposure or tobacco smoke [18,19].
To gain insight into the genomes of microsatellite stable and
instable colorectal cancers and to identify functional relevant
mutational patterns we used a hybridization based whole exome
DNA capturing approach followed by 454 next generation
sequencing [20]. Applying stringent bioinformatics analyses, we
narrowed down the amount of functionally significant somatic
mutations in MSI to 359 and 45 in MSS cancers, thus highlighting
specific mutation patterns depending on the microsatellite status.
We were able to confirm our results by sequencing the exomes of
four additional CRC cases (one MSI, three MSS) using a different
enrichment and sequencing technology. Among these mutations
are BRAF in the MSI cancer and KRAS and TP53 in the MSS
cancer, further underscoring the validity of our selection approach
[21]. Further functional characterizations identified recurrent
somatic mutations in BMPR1A, a protein which has been
associated so far with juvenile polyposis syndrome, a cancer
predisposition syndrome.
Results
Sequence-specific enrichment and sequencing strategy
We sequenced tumor and matching normal colon tissues from
two patients with high grade adenocarcinoma of the colon (G3),
patient 1 with a microsatellite instable and patient 2 with a
microsatellite stable tumor (Table 1, Figure S1). For the
determination of germline mutations we sequenced in addition
to the tumor tissues from each patient adjacent not affected
normal colonic tissue. Using Illumina sequencing and SNP arrays
we determined that the tumor of patient 1 is copy number stable
whereas patient 2 showed variations which we used for the re-
evaluation of identified high stringency mutations (Table S3).
We analyzed the complete exomes of more than 135,000 exons
with single-read shotgun 454 sequencing (Figure 1, Figure S1,
Figure S2, Table 2). To assess the effect of coverage depth on the
sensitivity and specificity of sequence variant detection, genotype
calls of the Affymetrix SNP array 6.0 were compared step-wise to
the called nucleic acid positions and resulted in an accuracy of
more than 99% (Figure S3). In addition to the SNP array, we used
Sanger sequencing to confirm 23 selected mutations (Table S5,
Figure S5).
Identification of somatic mutations in coding sequences
for a MSI CRC
Searching for variants in coding regions we found 12,767 and
12,518 small nuclear variations in 6,428 and 6,205 genes, for
tumor and normal respectively. Of these variants 1,428 for control
and 2,404 for tumor have an average heterozygosity or minor
allele frequency lower than 1% or have not been previously
reported in dbSNP or the 1000 Genomes Project (Figure 2). Since
indels (small insertions and deletions) at homopolymeric sites are a
major source of sequencing errors of the 454 platform we ignored
this type of alteration in our analyses.
Our somatic variant detection strategy was designed to
minimize false positive somatic variant calls rather than to
determine zygosity. We used a two-step approach with two
different stringency levels to detect variants in tumor and benign
tissues similar to Pleasance et al. [18]. In the first step, tumor
variants were called under stringent criteria, which were
determined by comparison to the SNP genotyping array data.
The second step ascertained whether the tumor variant was
germline or somatic. To keep the false negative rate in the benign
tissue at less than 10%, we set the coverage cut-off at 5-fold, below
which no conclusions were drawn regarding whether a variant was
somatic or germline. If the coverage cut-off was met, a single read
showing the same variant in benign and tumor tissue resulted in
the categorization of the variant as germline.
Using this strategy we identified 915 somatic non-synonymous
mutations affecting 864 genes. The majority of somatic mutations
were missense mutations (65%). However, many (7%) are located
within untranslated regions of genes and might therefore result in
altered expression or increased decay of mRNA species.
Furthermore, approximately 0.5% of these mutations are found
at splice sites and could influence splicing events, leading to an
altered transcriptome structure. In addition, three somatic variants
were identified in miRNA regions (Table S6). These mutations are
of particular interest because miRNAs have been implicated as
master regulators of tumor homeostasis. Analysis of the specific
types of nucleic acid variations, including known and unknown
variants, showed essentially the expected rates of nucleotide
exchanges, as determined by calculations using dbSNP130
(Figure S4).
Functional analysis of mutations for a MSI colon cancer
Since not all of the 1,304 somatic mutations are likely to be
pathologically relevant, we sought to identify those that probably
destroy protein function or affect highly conserved amino acids
and might therefore be functionally important. We used Polyphen
and MutationTaster classification tools to predict the functional
consequences of amino acid changes or frameshift mutations and
found that 359 genes had at least one potentially destructive
mutation (Table S1) [22,23].
Of the potentially destructive somatic mutations, 309 were
located in positions highly conserved in 44 different species,
including opossum (Monodelphis domestica), chicken (Gallus gallus)
and lamprey (Petromyzon marinus). Of these, 259 were located
in genes expressed in the colon, of which 47 were repair, receptor,
or kinase genes. Visualization of selected mutations on protein
structures indicates that these nucleotides are on the
protein surface, potentially resulting in disrupted protein-protein
interactions.
The Catalog of Somatic Mutations in Cancer (COSMIC)
database is a comprehensive collection of cancer-related muta-
Table 1. Colorectal cancer patients selected for NGS.
Patient 1 Patient 2
Age 59 65
Gender male Male
Grade G-3 G-3
Localization proximal CRC proximal CRC
MS status MSI MSS
CNV no Yes
doi:10.1371/journal.pone.0015661.t001
Exome Sequencing of MSI and MSS Colon Cancer
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described in this database, and 13% were found by Wood et al
[10]. As did these previous databases, we found the BRAF
p.V600E mutation in the MSI case and we identified KRAS and
TP53 mutations in the MSS tumor. BRAF mutations are found in
approximately 10% of CRCs, predominantly MSI and 30 to 35%
of all patients with sporadic colorectal cancers carry somatic KRAS
and TP53 mutations. These findings further demonstrate the
sensitivity of our classification strategy.
Mutational landscape of a MSS colon cancer
For the MSS colon cancer we identified 10,622 small nuclear
variations. After the same filtering processes as for the MSI cancer
using the dbSNP database and the data from the 1000 Genomes
Project 1,288 variants remained which either had low prevalence
or were unknown. Of these, 198 were somatic and 45 were
predicted to alter gene function based on MutationTaster and
Polyphen calculations (Figure 2B, Table S2) [22,23]. In regard to
copy number variations five of the 45 identified mutations are
located within amplified regions, and, as expected, none in regions
with deletions. The ratios of reads with reference sequence to
mutated sequence are not exceeding ratios in copy number stable
areas which supports the SNV-calling algorithm.
In contrast to 1,304 somatic mutations in the MSI tumor we
found 198 somatic mutations in the MSS tumor which demon-
strates that the defective MMR system in MSI tumors results in a
significant increase in mutation rates in colorectal cancer.
Furthermore, looking at intersections between both cancer types
we found BMPR1A, WDTC1 (WD and tetratricopeptode repeats
1) and EHD3 (EH-domain containing 3) mutated in both tumors.
The selection was based on functional impairment with high
probability in Polyphen and MutationTaster [22,23]. All muta-
tions are located on the surface of the protein and are highly
conserved. Since we found significant cancer-related pathways
associated only with BMPR1A but not with WDTC1 or EHD3,
and in addition germline mutations in BMPR1A are a known risk
factor for juvenile polyposis syndrome, we chose BMPR1A for
additional functional assays (Figure 3, Figure S5). Using reporter
assays with wild type and mutated BMPR1A proteins we were able
to show that the mutated proteins are strongly impaired in their
signalling function and that stimulation with BMP2 results in a
reduced maximum activity (Figure 3D).
Figure 1. Qualities of the targeted whole exome sequencing approach. (A) Venn diagram of captured exons of normal and tumor samples.
Captured exons with at least one read were counted. (B) Representative normalized coverage-distribution plot. The fraction of bait-covered exons in
the genome achieving coverages equal or lower than the normalized coverage is indicated on the x-axis. The mean coverage per exon was divided
by the mean coverage of all exons.
doi:10.1371/journal.pone.0015661.g001
Table 2. Tumor and normal genome coverages from MSI and MSS cancer patients.
Patient 1 Patient 2
normal tissue tumor tissue normal tissue tumor tissue
mapped reads (% of all reads) 5,659,707 (99.67%) 5,569,487 (97.21%) 2,425,905 (97.17%) 4,624,656 (96.71%)
unique mapped reads (% of all reads) 5,180,233 (91.23%) 5,285,822 (92.26%) 2,304,598 (92.38%) 4,367,855 (91.34%)
unique mapped bases (bp) (% of all bases) 1,978,702,340 (92.18%) 2,045,499,143 (88.22%) 883,388,420 (94.62%) 1,916,322,803 (94.53%)
median read length (bp) 393 418 418 483
unique reads in target region (% of all reads) 4,501,660 (79.28%) 4,477,985 (78.16%) 1,919,239 (67.88%) 3,640,778 (76.14%)
Target Base Coverage (%) 95.58 94.82 93.79 94.96
regions hit (of 176,159) 150,763 149,121 142,982 143,424
doi:10.1371/journal.pone.0015661.t002
Exome Sequencing of MSI and MSS Colon Cancer
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somatic mutations than MSS cancers
The analyses presented so far have been based on 454 whole
exome sequencings of one colorectal cancer patient for each
microsatellite status. To further confirm that the increased amount
of coding mutations in MSI cancers can be generalized and is not
due to the technology used (‘array’ enrichment and 454
sequencing) we sequenced the exomes of four additional colorectal
cancers, each with matching normal tissues. This time we used ‘in
solution hybridization’ for capturing of DNA followed by SOLiD
sequencing. After the same filtering procedures as described for
the first two patients we again determined up to 8-fold higher
mutation rates for the MSI colorectal cancer than for MSS cancers
(Table 3). In this regard we found 532 non-synonymous somatic
SNVs in the additional MSI CRC and only 65, 74 and 76 in the
three MSS CRC cases. Thus, the differences in mutation rates are
reproducible and independent of the sequencing technology used.
Discussion
Using next-generation sequencing, we sequenced the exomes of
MSS and MSI colon cancer patients, with mean coverages of
approximately 20-fold. We applied a two-sided classification
algorithm to uncover functionally relevant mutations. Using this
approach, we demonstrate for the first time that an array-capture
Figure 2. Identification process of somatic relevant SNVs. (A) Schematic of the bioinformatics SNV detection workflow. (B) Extraction of
functionally relevant somatic mutations for MSI and MSS colorectal cancers. Variants were detected with the GS Reference Mapper before they were
filtered for their localization, annotation in dbSNP130 or the 1000genomes, somatic and functionally impairment. From dbSNP130 or the
1000genomes variants with frequencies above 1% were used. For MSI CRC 359 variants and for MSS CRC 45 with predicted altered protein functions
were identified.
doi:10.1371/journal.pone.0015661.g002
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ization of solid tumors and show that MSI tumors carry eight times
more functional relevant mutations than MSS tumors (Figure 2).
The functional impact of the somatic variations was predicted
using two functional prediction algorithms, Polyphen and
MutationTaster, and we found 359 somatic mutations for the
MSI and 45 for the MSS cancer that are highly likely to cause
functional impairment [22,23]. The heterogeneity of mutated
genes suggests that not a specific gene per se but the affected
pathway plays a major role for tumor development. In this regard
we find a significant enrichment of mutations in cancer-related
pathways such as cancer, cellular development and DNA
replication, recombination and repair (Table S5). Interestingly,
we find 50% of the most significant enriched pathways in the MSS
cancer also as significantly enriched pathways for the MSI cancer,
indicating that even though MSI cancers harbour an increased
number of mutations both cancers might develop through
overlapping pathomechanisms.
Historically, microsatellite testing in colorectal cancers was the
first predictive test for the identification of an underlying mismatch
repair (MMR) mutation. Since more than 90% of hereditary non-
polyposis colorectal cancers (HNPCC) show MSI, the microsat-
Figure 3. Characterization of primary identified SNVs. (A) Proportional Venn diagram. Fractions of called SNVs identical to the Genomes
Project data and dbSNP130. Only data for which the minor allele frequency or the average heterozygosity was known and below 1% were used for
comparison. (B) Distribution of synonymous, missense, nonsense and mutations affecting the start or stop codon are shown in relation to all somatic
mutations. (C) BMPR1A mutations p.W487R and p.E502G are located at the protein kinase domain of BMPR1A. Reference amino acids are in green, the
mutated forms are shown in red. The net structure at the left lower side indicates the ATP binding domain. (D) BMPR1A mutations show decreased
signaling acitivity. Activity of wt mBMPR1A, mBMPR1A E502G and mBMPR1A W487R was determined in C2C12 cells using a SMAD-responsive
Luciferase reporter gene assay. Induced Luciferase activity was normalized to Renilla acitivty. The activity of untransfected cells was set to 0% and
the activity of wt mBmpr1a was set to 100%. Significant differences were calculated with a two-tailed t-test and marked as: * p#0.05, ** p#0.01,
*** p#0.001.
doi:10.1371/journal.pone.0015661.g003
Table 3. Distribution of SNVs in MSI and MSS tumors.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
MS status MSI MSS MSS MSS MSS MSI
enrichment technology array array in solution In solution in solution in solution
NGS technology 454 454 SOLiD SOLiD SOLiD SOLiD
number of mutations* 897 124 65 74 76 532
*non-synonymous somatic mutations, not annotated in dbSNP.
doi:10.1371/journal.pone.0015661.t003
Exome Sequencing of MSI and MSS Colon Cancer
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addition, survival advantages and therapeutic consequences have
been reported for patients with MSI tumors [5,24]. Using
ultradeep sequencing of one conserved region, UCR41, de Grassi
and colleagues show that this region has higher mutation rates in
HNPCC samples than in healthy controls and suggest that this
might be used as sensitive molecular assay of genomic instability
[24]. We have extended their analyses to whole exomes and found
8-fold differences in the numbers of somatic mutation of MSI and
MSS colorectal cancers. In comparison, a study by Greenman et al.
which reported on the sequencing of 518 protein kinase genes in
210 diverse human cancers found an approximately 25-fold higher
mutation rate for MMR-deficient cancers [9]. However, these are
extrapolations and in contrast to our study they included tumors
from different origins and examined all somatic mutations
irrespective of their functional relevance. With our sequencing
approach we also detected a somatic MLH3 mutation in the MSI
tumor, which, even though MLH3 mutations do not belong to the
classical MMR mutations in CRC, might contribute to the
microsatellite instability phenotype [25]. Furthermore, the com-
bination of MSI and BRAF mutation, as detected for the MSI
tumor described, is most frequently found for CpG island
methylation phenotype 1 (CIMP1) tumors which are associated
with MLH1 promoter methylations [21,26]. The promoter
methylation in turn is associated with gene silencing mechanisms
which is suggestive as an explanation for the MSI status of the
tumors. On the other side, it has been proposed that chromosomal
instability (CIN) and CIMP represent two independent and
inversely related mechanisms of instability [27]. CIMP-negative
cases are associated with p53 (71%) and KRAS (33%) mutations,
but are rarely found with BRAF (2%) mutations. Since we found
large copy number variations as well as KRAS and TP53 mutations
in the MSS tumor analyzed this tumor is most likely CIMP-
negative [5,24].
The sequencing and analysis strategy we have presented might
be the basis for future classification tools for colorectal cancers
because it may allow a parallel detection of an increased mutation
frequency in MSI tumors as well as the detection of the underlying
MMR defect. In addition, we were able to detect mutations of
genes frequently associated with certain subtypes of colorectal
cancers such as BRAF, KRAS and TP53. Within our high priority
genes, encompassing all genes which pass all selection filters,
BMPR1A stands out as mutated in both cases. The overall
structure reveals that the mutated amino acids are all located at
the C-terminal intracellular helix bundle at the protein kinase
domain and suggests that protein-protein interactions are
destroyed [28]. Germline BMPR1A mutations predispose to
juvenile polyposis syndrome; however, our findings indicate that
also somatic mutations might play an important role in sporadic
colorectal cancer development [29,30,31,32,33].
Besides these mutations we have also identified several mutated
cancer drug targets or genes that are associated with treatment
outcome, including BRAF, KRAS, FGFR2 and MTOR, which might
help to choose optimal drug combinations. As such similar
targeted re-sequencing approaches and bioinformatics filtering
strategies might become a gold standard for individually tailored
colorectal cancer treatment in the future.
Materials and Methods
Ethics Statement
The study has been approved by the Ethical Committee of the
Medical University of Graz. For new samples patients have given
their written informed consent. For old samples (15 years old) no
informed consent was available, therefore all samples and medical
data used in this study have been irreversibly anonymized.
Case presentation and tissue sample collection
Patient 1 had a high-grade (G3) adenocarcinoma of the
proximal colon, staged pT-3C, pN-0, pM-X, pR-0, microsatellite
instable (Figure 1A). In addition, this case was selected because of
its chromosomal stability, as determined using genome-wide next
generation sequencing (NGS) (Figure 1B). Patient 2 had a high-
grade (G3) adenocarcinoma of the proximal colon, staged pT-4B,
pN-2, pM-X, microsatellite stable.
Human tissue obtained during surgery was snap-frozen in liquid
nitrogen. Cryosections (3 mm thick) were prepared and stained
with haematoxylin and eosin to evaluate tumor cell content.
Dissections were performed under the microscope to achieve a
tumor cell content of .80%. DNA isolation was performed using
the QIAamp DNA Mini Kit (Qiagen), according to the
manufacturer’s instructions.
Whole Exome DNA Enrichment and Genome Sequencer
FLX sequencing
Genomic DNA of both tissues was subjected to whole exome
sequence capture using Roche/NimbleGen’s 2.1M Human
Exome Array. This array is based on build 36.3 of the human
genome sequence, and captures the coding regions of 16,755
NCBI RefSeq genes (approximately 180,000 coding exons) as well
as 493 miRNA regions. Tumor and normal tissue DNA were
subjected to whole exome sequence capturing according to the
manufacturer’s protocol. DNA was sheared by nebulization to
fragment sizes below 800bp, cleaned (Zymo Research) and end-
polished using T4 DNA Polymerase and T4 Polynucleotide
Kinase. Linker adapters pSel3 (59 – CTCGAG AAT TCT GGA
TCC TC – 39) and pSel4-P (59 – Phos/GAG GAT CCA GAA
TTC TCG AGT T – 39) were ligated and size selection was
performed using AMPure DNA Purification Beads (Agencourt).
Quality was controlled with the Bioanalyzer system. LM-PCR was
performed with LMPCR3 primers (59 – CUC GAG AAU UCU
GGA UCC UC – 39) before the library was used for hybridization
at 42uC for 72h. The arrays were washed two times at 47.5uC, two
times at room temperature and two times at 42uC with washing
buffers as recommended. Bound genomic DNA was eluted with
125 mM NaOH for 10 min at room temperature and amplified
by LM-PCR using primers LMPCR3. Captured amplified
samples were subjected to quantitative PCR to measure the
relative enrichment.
The enriched Nimblegen DNA was used to construct single-
stranded Genome Sequencer FLX (454/Roche) libraries. After
emulsion PCRs sequencing primers were annealed to the template
and beads were incubated with Bst DNA polymerase, apyrase, and
single-stranded binding protein. Pyrosequencing was performed on
a7 0 675 mm picotiter plate in 13 separate sequencing runs. After
default rawdata processing, a resequencing trimming filter was used
to increase the data output. (Parameters used: doValleyFilterTrim-
Back = false, vfBadFlowThreshold =6, vfLastFlowToTest =168,
errorQscoreWindowTrim =0.01).
For the sequencing we performed 13 Genome Sequencer FLX
runs, which produced over 558 million bases and 1.43 million
reads per run. Reads were aligned to the human reference
genome, NCBI build 36 (http://hgdownload.cse.ucsc.edu/
goldenPath/hg18/), using GS Reference Mapper Version
2.0.0.12 (Roche). The best matches in the genome were used as
the location for the reads with multiple matches. Only unique
reads with a minimum length of 50 bp were used for further
analysis (see run statistics Tab. 2).
Exome Sequencing of MSI and MSS Colon Cancer
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Mapper Version 2.0.0.12 (Roche). Redundant reads were
subtracted before variant callings. Only the HCDiff (high
confidence differences) of the GS Mapper software were used as
basis of variant detection [20]. HCDiff callings presume at least
three reads with the variant with both forward and reverse reads
included; alternatively the quality scores at the variable positions
must be over 20 (or over 30 if a homopolymer of five or more
bases is involved). As additional quality criteria we used only
variants with a coverage .106of high quality reads.
Whole Exome ‘in solution’ DNA Enrichment and SOLiD
sequencing
Enrichments and SOLiD library preparation were performed
according to Agilent’s SureSelect Target Enrichment protocol for
the Applied Biosystems SOLiD system. In brief, whole genomic
DNA was sheared and end repaired. For adapter ligations 30x
excess of the adapters were used. Size selections for 150–200 bp
DNA fragments were performed followed by a nick-translation
and amplification step with Platinum polymerase (Invitrogen) and
Pfu-Polymerase (Fermentas). For hybrid selection the libraries
were adjusted to 500 ng in 3.4 ml volume and added to the
SureSelect Block solutions. Hybridizations were performed for
24 h at 65uC, hybrids were extracted with 500 ng M-280
streptavidin Dynabeads (Invitrogen) and finally eluted with 50 ml
Elution buffer. After amplification with Platinum polymerase the
libraries were quantified by qPCR and DNA concentration was
titrated to achieve a fraction of 10–20% monoclonal template
beads in the emulsion PCR using in total 0.7 to 1 billion beads.
Successive bead enrichment and deposition of 130 million beads
per quarter slide (quad) was followed by standard 50 bp fragment
runs. Each of the four patient samples was analyzed on a single
quad.
Mapping was performed with the Bioscope alignment pipeline
using the seed & extend algorithm with a mismatch penalty score
22.0. Single Nucleotide Variants (SNV) were called with the
DiBayes algorithm integrated in the Bioscope package.
Single nucleotide variant (SNV) detection
Tissue materials were genotyped on the Affymetrix 6.0 array,
according to the manufacturer’s protocol. Array positions with a
quality score (p-value) ,0.1 were used for comparison with the
sequencing data. Sequencing data positions were used if their
coverage exceeded 3-fold. This generated 46,000 and 49,000
positions for tumor and benign tissue, respectively, that were
eligible for comparison. To determine false positive and false
negative rates, we set the array data as standard and distinguished
between reference call and SNP call dependence on the array
data.
For the detection of somatic variants, a bimodal strategy was
applied with tumor variants called under stringent criteria,
whereas variants in control tissue were called using less stringent
criteria: A minimum threshold for reads was set with variants of
15% of all reads at a given position in tumor. Less stringent criteria
were used for calling control tissue variants with a minimum of one
variant read and a minimum coverage cutoff of 5. For coverages
above 30-fold one variant read was accepted.
Capillary Sequencing
Follow-up confirmation of identified SNVs was performed on
an ABI 3730 (Applied Biosystems) capillary sequencing instrument
following standard procedures.
Determination of Copy number variations
Preparation of single read libraries and sequencing were
performed using the Solexa sequencing platform (GenomeAnaly-
zer IIx, Illumina) following the manufacturer’s instructions. Image
Analysis and base calling were performed using Firecrest 1.9.5_14
and Bustard 1.9.5_14 and reads were aligned to the human
genome (NCBI36) using Bowtie 0.9.7.1 [34]. Copy number
analysis was done in R using the DNAcopy package [35]. In short,
DNA read frequencies were determined for bins of 50 Kb. The
log2 frequency ratio of corresponding bins was calculated for
tumor versus normal tissue. Median of ratios was centered to zero
experiment wise. Log ratios were smoothed by DNAcopy using
default values and copy number variation was detected by
DNAcopy using a threshold of two standard deviations.
Genotyping on the Affymetrix 6.0 array was performed
according to the manufacturer’s protocol. Regions of copy number
gain and loss were determined by paired and analysis using the
Hidden Markov Model (HMM) of the Partek Genomics Suite
software (Partek Inc, St.Louis, MO) with default parameter
settings. For paired analysis, copy number values were generated
by comparing tumor and benign tissue profiles from the same
patient.
Bioinformatics workflow
For each tissue, variations were annotated using the gene
models generated by Ensembl (ensembl 54.36, www.ensembl.org).
All variations were mapped to all transcript models, which led to
multiple annotations for several loci. For instance, a variant can
lead to an amino acid change in one transcript and appear in the
UTR of another. Comparison of tumor and benign tissue variants
to dbSNP130 and 1000 Genomes Project data was carried out
with the subset of dbSNP130 and 1000 Genomes Project positions
with minor allele frequencies or average heterozygosity .0.01.
Variants were subjected to many comparisons with external
data sources. Most data sources are integrated in the UCSC
genome browser (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/
database/) or were derived from websites like the 1000 Genomes
Project (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/2009_
04/) the gene ontology data (http://archive.geneontology.
org/full/2009-10-01/go_200910-termdb.obo-xml.gz), the cosmic
database version 46 (http://www.sanger.ac.uk/genetics/CGP/
cosmic/) or the cancer gene census database (http://www.
sanger.ac.uk/genetics/CGP/census/). Functional classifications
were performed using Polyphen and MutationTaster classification
tools (http://genetics.bwh.harvard.edu/pph/, http://neurocore.
charite.de/MutationTaster/) [22,23]. Base conservation among 44
species was tested using the phyloP track of the UCSC browser
(http://genome.cshlp.org/content/early/2009/10/26/gr.
097857.109.abstract). Bases were considered highly conserved if
their conservation score was greater or equal 2.0 (0.975 quantil of
all conservation scores). For gene expression healthy control sam-
ples from http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=
GDS2609 were used. We calculated genewise mean expression
values across all samples and used the first quartile as threshold to
determine gene expression. Pathway analyses were performed with
the ingenuity pathway analysis tool (http://www.ingenuity.com).
All new data from this study has been deposited at NCBI dbSNP
database of genetic variation (user-name MPIMGCanceroge-
nomics). Accession numbers are included as Table S4.
Protein structure modeling
Models for BMPR1A were obtained from SwissModel and
ModBase. Very similar models except for some loops (total Calpha
rmsd 0.66) were rendered in PyMol [36,37].
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The activity of the wildtype mouse protein (wtmBMPR1A) and
its mutants was determined by measuring induced Luciferase
activity in the transiently transfected pre-myoblastic mouse cell
line C2C12 (ATCC). WtmBMPR1A was amplified from mouse
cDNA and cloned in the expression vector pCS2+. Both mutations
W487R and E502G were inserted by Quikchange mutagenesis
(Stratagene) using the following primer pairs:
mBmpr1a_W487R_fwd caatcgtgtctaaccgcCggaacagcgatgaatg;
mBmpr1a_W487R_rev cattcatcgctgttccGgcggttagacacgattg and
mBmpr1a_E502G_fwd gttttgaagctaatgtcagGatgttgggcccataatc;
mBmpr1a_E502G_rev gattatgggcccaacatCctgacattagcttcaaaac.
C2C12 cells were cultured in DMEM glucose 4,5 g/L with
10% FCS were co-transfected with each Bmpr1a expression
construct, a Smad Binding Element (SBE) luciferase construct [38]
and the normalization vector pRL-Tk (Promega Corporation,
Madison, WI, USA) using Turbofect (Fermentas GmbH, St. Leon-
Rot, Germany). Luciferase activity was determined as described
previously [39].
Supporting Information
Figure S1 Quality controls of the colon cancer case 1 and
experimental performances. (A) Visualization of Copy number
variations (CNV) using Illumina sequencing for MSI and MSS
cancers. Chromosomal coverage ratio of tumor versus benign
tissue sample. Each chromosome was divided into 50-kb bins. The
log2 ratios of unique reads per bin are plotted across all
chromosomes. The red lines depict the local averages as calculated
by DNAcopy [35]. (B) Influence of sequencing depth on exon
capture coverage (left) and SNV detection (right). Exon coverage
and SNVs in the enrichment regions were determined after each
sequencing run. The numbers of exons covered and the number of
SNVs detected at different coverage levels were compared for
tumor and benign tissue separately. Sigmoid functions Y=c+
(d-c)/(1+exp(b)*(log(X)-log(e)) were used to fit the data and
extrapolate the saturation level.
(TIF)
Figure S2 Sequence coverage along a contiguous target. (A) The
base-by-base sequence coverage along a typical 80-kb segment
(BRCA1 gene) in the UCSC browser is shown. The 10-fold
coverage level is highlighted by a black line. (B) Coverage profiles
of exon targets depending on exon size. Exons have been divided
into four groups depending on exon size. Coverages were
calculated in relation to the relative position on the exon and
averaged by the mean over all exons of the group.
(TIF)
Figure S3 Comparison between the SNP array and NGS. About
one million known SNP positions have been investigated using the
Affymetrix human whole genome SNP array 6.0. Array positions
with a quality score (p-value),0.1 and sequencing positions with
coverage exceeding 3-fold coverage were used for comparison.
Forty thousand and thirty-six thousand positions for tumor and
benign tissue, respectively, were eligible for comparison. To
determine false positive and false negative rates, the array data was
set as standard and between reference call and SNP call
dependence on the array data was distinguished. (A) homo- and
heterozygous SNVs were discerned (B) for the calculation of the
haploid concordances heterozygous positions were counted as
homozygous non-reference positions.
(TIF)
Figure S4 Nucleotide exchange rates in DNA from tumor and
benign tissue, as compared to dbSNP130 data for patient 1. (A)
Using the GS Reference Mapper Version 2.0.0.12 (Roche),
software nucleotide exchanges were calculated for all possible
transitions (e.g. A,.G, A,.C). Dark grey: tumor, grey: benign,
light grey: dbSNP (B) Dinucleotide context for single nucleotide
variants from tumor and benign tissue. Dark grey: tumor, grey:
benign, light grey: dbSNP
(TIF)
Figure S5 Validation, visualization and pathway analyses. (A)
Visualization of the Sanger and 454 next generation sequencing
result of BMPR1A. Red arrows indicate the location of the
mutation. (B) Ingenuity pathway analysis of BMPR1A, WDTC1,
EHD3 and CTR9 (top) and visualization of the conservation of
BMPR1A p.W487 and p.E502 across human, mouse, chicken,
zebrafish and other organisms (bottom).
(TIF)
Table S1 List of 359 somatic candidate genes with functionally
relevant mutations for the MSI colorectal cancer case. Column
headings are as follows: (A) Location, (B) Mutation, (C) coverage in
tumor, (D) number of reads with SNV in tumor, (E) coverage in
normal, (F) number of reads with SNV in normal, (G) amino acid
position, (H) amino acid, (I) mutated amino acid, (J) gene name,
(K-M) Ensembl transcript ID, Ensembl gene ID, Ensembl protein
ID, (N) nucleotide conservation (PhyloP), (O) protein domain, (P)
Polyphen, (Q) MutationTaster, (R) mean expression in colon, (S)
described in Wood et al.2007, (T) listed in COSMIC database, (U)
listed as CancerGeneCensus (dom=dominant (oncogene), re-
c=recessive (tumor suppressor)), (V-Y) listed in GO database as
repair gene, kinase, receptor, transmembrane receptor, (Z-AJ):
annotated within dbSNP130 (rs numbers indicate mutations with
frequencies above 1%), 1000 genomes, Venter genome, Watson
genome, Yoruban genome, Corean genome, Han genome,
genome 12891, genome 12878, genome 12892, genome 19240.
(XLS)
Table S2 List of 45 somatic candidate genes with functionally
relevant mutations for the MSS colorectal cancer case. Column
headings are as follows: (A) Location, (B) Mutation, (C) coverage in
tumor, (D) number of reads with SNV in tumor, (E) coverage in
normal, (F) number of reads with SNV in normal, (G) amino acid
position, (H) amino acid, (I) mutated amino acid, (J) gene name,
(K-M) Ensembl transcript ID, Ensembl gene ID, Ensembl protein
ID, (N) nucleotide conservation (PhyloP), (O) protein domain, (P)
Polyphen, (Q) MutationTaster, (R) mean expression in colon, (S)
described in Wood et al.2007, (T) listed in COSMIC database, (U)
listed as CancerGeneCensus (dom=dominant (oncogene), re-
c=recessive (tumor suppressor)), (V-Y) listed in GO database as
repair gene, kinase, receptor, transmembrane receptor, (Z-AJ):
annotated within dbSNP130 (rs numbers indicate mutations with
frequencies above 1%), 1000 genomes, Venter genome, Watson
genome, Yoruban genome, Corean genome, Han genome,
genome 12891, genome 12878, genome 12892, genome 19240.
(XLS)
Table S3 Copy number variations (CNVs) of the MSS colon
cancer case. Somatic amplifications and deletions were determined
with the Affymetrix 6.0 array followed by a paired Hidden Markov
Model analysis with the Partek genomics Suite software. Column
headings are as follows: Chromosome, start and end position of the
CNV, cytoband, copy number, length in bp and CNV state.
(XLS)
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CRC. Selected were pathways listed in the top 25 significantly
enriched pathways for the MSS cancer which were also found to
be highly significant in the MSS cancer.
(XLS)
Table S5 List of candidate locations used for capillary
sequencing. Column headings are as follows: (A) Chromosomal
localization, (B) validation with Sanger capillary sequencing, (C)
reference codon, (D) position of the mutation in the reference
codon, (E) mutated codon, (F) amino acid position, (G) total
amount of amino acids, (H) reference amino acid, (I) mutated
amino acid, (J) protein domain, (K-M) Ensembl transcript ID,
Ensembl gene ID, Ensembl protein ID, (N) gene name, (O) listed
in COSMIC database, (P) described in Wood et al.2007, (Q-AA):
annotated within 1000 genomes, dbSNP130, Venter genome,
Watson genome, Yoruban genome, Corean genome, Han
genome, genome 12891, genome 12878, genome 12892, genome
19240, (AB) number of reference reads in tumor, (AC) number of
mutated reads in tumor, (AD) number of reference reads in
normal, (AE) number of mutated reads in normal, (AF)
MutationTaster, (AG) Polyphen
(XLS)
Table S6 SNVs in miRNA regions. Column headings are as
follows: (A) Patient ID, (B,C) chromosomal localization, (D)
mirBase13 including the ID of the mutated miRNA, (E)
Percentage of reads with the mutation in the tumor tissue, (F)
Percentage of reads with the mutation in normal tissue, (G)
annotation of the SNV, (H) related gene name, (I) mutated
nucleotide, (J) annotation in dbSNP 130, (K) annotation in the
1000genomes project
(XLS)
Table S7 NCBI numbers of the identified SNVs.
(XLS)
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